Search

Your search keyword '"Zongo, Issaka"' showing total 326 results
Start Over Author "Zongo, Issaka"
326 results on '"Zongo, Issaka"'

1. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study.

Author

Roh, Michelle, Zongo, Issaka, Haro, Alassane, Huang, Liusheng, Somé, Anyirékun, Yerbanga, Rakiswendé, Conrad, Melissa, Wallender, Erika, Legac, Jennifer, Aweeka, Francesca, Ouédraogo, Jean-Bosco, and Rosenthal, Philip

Subjects
amodiaquine, antimalarial resistance, malaria, seasonal malaria chemoprevention, sulfadoxine-pyrimethamine, Humans, Child, Infant, Child, Preschool, Burkina Faso, Case-Control Studies, Seasons, Malaria, Antimalarials, Sulfadoxine, Amodiaquine, Chemoprevention, Drug Combinations, Drug Resistance
Abstract

BACKGROUND: Despite scale-up of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) in children 3-59 months of age in Burkina Faso, malaria incidence remains high, raising concerns regarding SMC effectiveness and selection of drug resistance. Using a case-control design, we determined associations between SMC drug levels, drug resistance markers, and presentation with malaria. METHODS: We enrolled 310 children presenting at health facilities in Bobo-Dioulasso. Cases were SMC-eligible children 6-59 months of age diagnosed with malaria. Two controls were enrolled per case: SMC-eligible children without malaria; and older (5-10 years old), SMC-ineligible children with malaria. We measured SP-AQ drug levels among SMC-eligible children and SP-AQ resistance markers among parasitemic children. Conditional logistic regression was used to compute odds ratios (ORs) comparing drug levels between cases and controls. RESULTS: Compared to SMC-eligible controls, children with malaria were less likely to have any detectable SP or AQ (OR, 0.33 [95% confidence interval, .16-.67]; P = .002) and have lower drug levels (P < .05). Prevalences of mutations mediating high-level SP resistance were rare (0%-1%) and similar between cases and SMC-ineligible controls (P > .05). CONCLUSIONS: Incident malaria among SMC-eligible children was likely due to suboptimal levels of SP-AQ, resulting from missed cycles rather than increased antimalarial resistance to SP-AQ.

Published
2023

2. Factors influencing second and third dose observance during Seasonal Malaria Chemoprevention (SMC): A quantitative study in Burkina Faso, Mali and Niger

Author

Some, Anyirekun Fabrice, Zongo, Issaka, Sagara, Issaka, Ibrahim, Alkassoum, Ahanhanzo, Cesaire Damien, Agbanouvi-agassi, Edoh Eddie, Sayi, Dona Alain, Toe, Lea Pare, Kabre, Zachari, Nikiema, Frederic, Bazie, Thomas, Ouedraogo, Sylvin, Sombie, Issiaka, Dicko, Alassane, Adehossi, Eric, Ouedraogo, Jean-Bosco, and Dabire, Kounbobr Roch

Published
2022

3. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Author

Mahamar, Almahamoudou, Sanogo, Koualy, Sidibe, Youssoufa, Diarra, Kalifa, Samassekou, Mamoudou, Attaher, Oumar, Tapily, Amadou, Diallo, Makonon, Dicko, Oumar Mohamed, Kaya, Mahamadou, Maguiraga, Seydina Oumar, Sankare, Yaya, Yalcouye, Hama, Diarra, Soumaila, Niambele, Sidi Mohamed, Thera, Ismaila, Sagara, Issaka, Sylla, Mala, Dolo, Amagana, Misidai, Nsajigwa, Simando, Sylvester, Msami, Hania, Juma, Omary, Gutapaka, Nicolaus, Paul, Rose, Mswata, Sarah, Sasamalo, Ibrahim, Johaness, Kasmir, Sultan, Mwantumu, Alexander, Annastazia, Kimaro, Isaac, Lwanga, Kauye, Mtungwe, Mwajuma, Khamis, Kassim, Rugarabam, Lighton, Kalinga, Wilmina, Mohammed, Mohammed, Kamange, Janeth, Msangi, Jubilate, Mwaijande, Batuli, Mtaka, Ivanny, Mhapa, Matilda, Mlaganile, Tarsis, Mbaga, Thabit, Yerbanga, Rakiswende Serge, Samtouma, Wendkouni, Sienou, Abdoul Aziz, Kabre, Zachari, Ouedraogo, Wendinpui Jedida Muriel, Yarbanga, G Armel Bienvenu, Zongo, Issaka, Savadogo, Hamade, Sanon, Joseph, Compaore, Judicael, Kere, Idrissa, Yoni, Ferdinand Lionel, Sanre, Tewende Martine, Ouattara, Seydou Bienvenu, Provstgaard-Morys, Samuel, Woods, Danielle, Snow, Robert W., Amek, Nyaguara, Ngetsa, Caroline J., Ochola-Oyier, Lynette Isabella, Musyoki, Jennifer, Munene, Marianne, Mumba, Noni, Adetifa, Uche Jane, Muiruri, Charles Mwangi, Mwawaka, Jimmy Shangala, Mwaganyuma, Mwatasa Hussein, Ndichu, Martha Njeri, Weya, Joseph Ochieng, Njogu, Kelvin, Grant, Jane, Webster, Jayne, Lakhkar, Anand, Ido, N. Félix André, Traore, Ousmane, Tahita, Marc Christian, Bonko, Massa dit Achille, Rouamba, Toussaint, Ouedraogo, D. Florence, Soma, Rachidatou, Millogo, Aida, Ouedraogo, Edouard, Sorgho, Faizatou, Konate, Fabé, Valea, Innocent, Datoo, Mehreen S, Dicko, Alassane, Tinto, Halidou, Ouédraogo, Jean-Bosco, Hamaluba, Mainga, Olotu, Ally, Beaumont, Emma, Ramos Lopez, Fernando, Natama, Hamtandi Magloire, Weston, Sophie, Chemba, Mwajuma, Compaore, Yves Daniel, Issiaka, Djibrilla, Salou, Diallo, Some, Athanase M, Omenda, Sharon, Lawrie, Alison, Bejon, Philip, Rao, Harish, Chandramohan, Daniel, Roberts, Rachel, Bharati, Sandesh, Stockdale, Lisa, Gairola, Sunil, Greenwood, Brian M, Ewer, Katie J, Bradley, John, Kulkarni, Prasad S, Shaligram, Umesh, and Hill, Adrian V S

Published
2024
Full Text
View/download PDF

4. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial

Author

Dicko, Alassane, Ouedraogo, Jean-Bosco, Zongo, Issaka, Sagara, Issaka, Cairns, Matthew, Yerbanga, Rakiswendé Serge, Issiaka, Djibrilla, Zoungrana, Charles, Sidibe, Youssoufa, Tapily, Amadou, Nikièma, Frédéric, Sompougdou, Frédéric, Sanogo, Koualy, Kaya, Mahamadou, Yalcouye, Hama, Dicko, Oumar Mohamed, Diarra, Modibo, Diarra, Kalifa, Thera, Ismaila, Haro, Alassane, Sienou, Abdoul Aziz, Traore, Seydou, Mahamar, Almahamoudou, Dolo, Amagana, Kuepfer, Irene, Snell, Paul, Grant, Jane, Webster, Jayne, Milligan, Paul, Lee, Cynthia, Ockenhouse, Christian, Ofori-Anyinam, Opokua, Tinto, Halidou, Djimde, Abdoulaye, Chandramohan, Daniel, and Greenwood, Brian

Published
2024
Full Text
View/download PDF

5. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study

Author

Beshir, Khalid B, Muwanguzi, Julian, Nader, Johanna, Mansukhani, Raoul, Traore, Aliou, Gamougam, Kadidja, Ceesay, Sainey, Bazie, Thomas, Kolie, Fassou, Lamine, Mahaman M, Cairns, Matt, Snell, Paul, Scott, Susana, Diallo, Abdoulaye, Merle, Corinne S, NDiaye, Jean Louis, Razafindralambo, Lanto, Moroso, Diego, Ouedraogo, Jean-Bosco, Zongo, Issaka, Kessely, Hamit, Doumagoum, Daugla, Bojang, Kalifa, Ceesay, Serign, Loua, Kovana, Maiga, Hamma, Dicko, Alassane, Sagara, Issaka, Laminou, Ibrahim M, Ogboi, Sonny Johnbull, Eloike, Tony, Milligan, Paul, and Sutherland, Colin J

Published
2023
Full Text
View/download PDF

7. The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone

Author

Cairns, Matthew, Barry, Amadou, Zongo, Issaka, Sagara, Issaka, Yerbanga, Serge R., Diarra, Modibo, Zoungrana, Charles, Issiaka, Djibrilla, Sienou, Abdoul Aziz, Tapily, Amadou, Sanogo, Koualy, Kaya, Mahamadou, Traore, Seydou, Diarra, Kalifa, Yalcouye, Hama, Sidibe, Youssoufa, Haro, Alassane, Thera, Ismaila, Snell, Paul, Grant, Jane, Tinto, Halidou, Milligan, Paul, Chandramohan, Daniel, Greenwood, Brian, Dicko, Alassane, and Ouedraogo, Jean Bosco

Published
2022
Full Text
View/download PDF

8. Impact of seasonal RTS,S/AS01E vaccination plus seasonal malaria chemoprevention on the nutritional status of children in Burkina Faso and Mali

Author

Grant, Jane, Sagara, Issaka, Zongo, Issaka, Cairns, Matthew, Yerbanga, Rakiswendé Serge, Diarra, Modibo, Zoungrana, Charles, Issiaka, Djibrilla, Nikièma, Frédéric, Sompougdou, Frédéric, Tapily, Amadou, Kaya, Mahamadou, Haro, Alassane, Sanogo, Koualy, Sienou, Abdoul Aziz, Traore, Seydou, Thera, Ismaila, Yalcouye, Hama, Kuepfer, Irene, Snell, Paul, Milligan, Paul, Ockenhouse, Christian, Ofori-Anyinam, Opokua, Tinto, Halidou, Djimde, Abdoulaye, Chandramohan, Daniel, Greenwood, Brian, Dicko, Alassane, and Ouédraogo, Jean-Bosco

Published
2022
Full Text
View/download PDF

9. Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study

Author

Ward, Charlotte, Phillips, Abimbola, Oresanya, Olusola, Olisenekwu, Gloria, Arogunade, Ekundayo, Moukénet, Azoukalné, Beakgoubé, Honoré, De Paul Allambademel, Vincent, Compaoré, Cheick Saïd, Traoré, Adama, Ouedraogo, Jean-Bosco, Compaoré, Yves Daniel, Zongo, Issaka, Donovan, Laura, Decola, Monica Anna, Smith, Helen, and Baker, Kevin

Published
2022
Full Text
View/download PDF

12. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study

Author

Baba, Ebenezer, Hamade, Prudence, Kivumbi, Harriet, Marasciulo, Maddy, Maxwell, Kolawole, Moroso, Diego, Roca-Feltrer, Arantxa, Sanogo, Adama, Stenstrom Johansson, Joanna, Tibenderana, James, Abdoulaye, Rahila, Coulibaly, Patrice, Hubbard, Eric, Jah, Huja, Lama, Eugene Kaman, Razafindralambo, Lantorina, Van Hulle, Suzanne, Jagoe, George, Tchouatieu, André-Marie, Collins, David, Gilmartin, Colin, Tetteh, Gladys, Djibo, Yacine, Ndiaye, Fara, Kalleh, Momodou, Kandeh, Balla, Audu, Bala, Ntadom, Godwin, Kiba, Alice, Savodogo, Yacouba, Boulotigam, Kodbesse, Sougoudi, Djiddi Ali, Guilavogui, Timothee, Keita, Moussa, Kone, Diakalidia, Jackou, Hadiza, Ouba, Ibrahim, Ouedraogo, Emile, Messan, Halimatou Alassana, Jah, Fatou, Kaira, Markieu Janneh, Sano, Mariama Sire, Traore, Mamadou Chérif, Ngarnaye, Nadine, Elagbaje, Aishatu Yinusa Cassandra, Halleux, Christine, Merle, Corinne, Iessa, Noha, Pal, Shanthi, Sefiani, Houda, Souleymani, Rachida, Laminou, Ibrahim, Doumagoum, Daugla, Kesseley, Hamit, Coldiron, Matt, Grais, Rebecca, Kana, Musa, Ouedraogo, Jean Bosco, Zongo, Issaka, Eloike, Tony, Ogboi, Sonny Johnbull, Achan, Jane, Bojang, Kalifa, Ceesay, Serign, Dicko, Alassane, Djimde, Abdoulaye, Sagara, Issaka, Diallo, Abdoulaye, NdDiaye, Jean Louis, Loua, Kovana Marcel, Beshir, Khalid, Cairns, Matt, Fernandez, Yolanda, Lal, Sham, Mansukhani, Raoul, Muwanguzi, Julian, Scott, Susana, Snell, Paul, Sutherland, Colin, Tuta, Rhosyn, and Milligan, Paul

Published
2020
Full Text
View/download PDF

14. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso

Author

Zongo, Issaka, Milligan, Paul, Compaore, Yves Daniel, Some, A Fabrice, Greenwood, Brian, Tarning, Joel, Rosenthal, Philip J, Sutherland, Colin, Nosten, Francois, and Ouedraogo, Jean-Bosco

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Malaria, Infectious Diseases, Clinical Trials and Supportive Activities, Vector-Borne Diseases, Rare Diseases, Orphan Drug, Prevention, Pediatric, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Amodiaquine, Antimalarials, Artemisinins, Burkina Faso, Case-Control Studies, Chemoprevention, Child, Preschool, Drug Combinations, Drug Resistance, Drug Therapy, Combination, Female, Humans, Infant, Male, Pyrimethamine, Quinolines, Seasons, Sulfadoxine, Microbiology, Pharmacology and Pharmaceutical Sciences, Medical microbiology, Pharmacology and pharmaceutical sciences
Abstract

The WHO recommends that children living in areas of highly seasonal malaria transmission in the Sahel subregion should receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ). We evaluated the use of dihydroartemisinin-piperaquine (DHAPQ) as an alternative drug that could be used if SPAQ starts to lose efficacy. A total of 1,499 children 3 to 59 months old were randomized to receive SMC with SPAQ or DHAPQ over 3 months. The primary outcome measure was the risk of clinical malaria (fever or a history of fever with a parasite density of at least 3,000/μl). A cohort of 250 children outside the trial was followed up as a control group. Molecular markers of drug resistance were assessed. The risk of a malaria attack was 0.19 in the DHAPQ group and 0.15 in the SPAQ group, an odds ratio of 1.33 (95% confidence interval [CI], 1.02 to 1.72). Efficacy of SMC compared to the control group was 77% (67% to 84%) for DHAPQ and 83% (74% to 89%) for SPAQ. pfdhfr and pfdhps mutations associated with antifolate resistance were more prevalent in parasites from children who received SPAQ than in children who received DHAPQ. Both regimens were highly efficacious and well tolerated. DHAPQ is a potential alternative drug for SMC. (This trial is registered at ClinicalTrials.gov under registration no. NCT00941785.).

Published
2015

15. Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Author

Compaoré, Yves Daniel, Zongo, Issaka, Somé, Anyirékun F., Barry, Nouhoun, Nikiéma, Frederick, Kaboré, Talato N., Ouattara, Aminata, Kabré, Zachari, Wermi, Kadidiatou, Zongo, Moussa, Yerbanga, Rakiswende S., Sagara, Issaka, Djimdé, Abdoulaye, and Ouédraogo, Jean Bosco

Published
2021
Full Text
View/download PDF

18. Nutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria

Author

de Wit, Mariken, Cairns, Matthew, Compaoré, Yves Daniel, Sagara, Issaka, Kuepfer, Irene, Zongo, Issaka, Barry, Amadou, Diarra, Modibo, Tapily, Amadou, Coumare, Samba, Thera, Ismaila, Nikiema, Frederic, Yerbanga, R. Serge, Guissou, Rosemonde M., Tinto, Halidou, Dicko, Alassane, Chandramohan, Daniel, Greenwood, Brian, and Ouedraogo, Jean Bosco

Published
2021
Full Text
View/download PDF

19. Efficacy, safety, tolerability of Dihydroartemisinine-Piperaquine and Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention (SMC) in children in Burkina Faso

Author

Zongo, Issaka and Milligan, P.

Subjects
618.92
Abstract

Children in areas of highly seasonal malaria transmission in the Sahel should receive SMC with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ). These drugs retain their efficacy in the areas where SMC is recommended, but alternative regimens are needed if SMC is used in other areas or if these drugs start to lose efficacy. The aim of this study was to investigate the suitability of dihydroartemisin-piperaquine (DHAPQ) for SMC, using a non-inferiority trial design. 1500 children randomized to receive SPAQ or DHAPQ monthly from August to October, and a cohort of untreated children outside the trial, were followed-up for malaria. SPAQ was more efficacious than DHAPQ, but the difference was within the margin set for non-inferiority. Both regimens gave a very high level of protection lasting 4 weeks. Protection was related to dosage. Both regimens were well tolerated, incidence of mild adverse events decreased in successive months, consistent with toleration to study drugs. In malaria cases, the frequency of the CVIET haplotype of pfcrt, the 86Y polymorphism of pfmdr1, and pfdhfr59 and dhps437 mutations, was greater among children who received SPAQ than in untreated children. However the number of cases, and the prevalence of parasitaemia, was much lower in treated children, reducing the scope for SMC to select for resistance. The frequency of the CVIET haplotype of PfCRT, thought to be associated with resistance to PQ, was not increased in children treated with DHAPQ. There was an enormous burden of malaria in the untreated children. SMC with SPAQ should be introduced for children in Burkina Faso without delay. DHAPQ is a potential alternative regimen in areas where SPAQ cannot be used but there are some drawbacks associated with its use. There is a need to develop alternative long-acting drugs with simple regimens that can be used for chemoprevention of malaria.

Published
2014
Full Text
View/download PDF

20. Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso

Author

Somé, Anyirékun Fabrice, Zongo, Issaka, Compaoré, Yves-Daniel, Sakandé, Souleymane, Nosten, François, Ouédraogo, Jean-Bosco, and Rosenthal, Philip J

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Genetics, Vector-Borne Diseases, Infectious Diseases, Malaria, Rare Diseases, Orphan Drug, Clinical Research, Prevention of disease and conditions, and promotion of well-being, 3.3 Nutrition and chemoprevention, Infection, Good Health and Well Being, Antimalarials, Burkina Faso, Child, Child, Preschool, DNA, Protozoan, Drug Resistance, Humans, Infant, Malaria, Falciparum, Plasmodium falciparum, Polymorphism, Genetic, Rural Population, Seasons, Microbiology, Pharmacology and Pharmaceutical Sciences, Medical microbiology, Pharmacology and pharmaceutical sciences
Abstract

Seasonal malaria chemoprevention (SMC), with regular use of amodiaquine plus sulfadoxine-pyrimethamine (AQ/SP) during the transmission season, is now a standard malaria control measure in the Sahel subregion of Africa. Another strategy under study is SMC with dihydroartemisinin plus piperaquine (DP). Plasmodium falciparum single nucleotide polymorphisms (SNPs) in P. falciparum crt (pfcrt), pfmdr1, pfdhfr, and pfdhps are associated with decreased response to aminoquinoline and antifolate antimalarials and are selected by use of these drugs. To characterize selection by SMC of key polymorphisms, we assessed 13 SNPs in P. falciparum isolated from children aged 3 to 59 months living in southwestern Burkina Faso and randomized to receive monthly DP or AQ/SP for 3 months in 2009. We compared SNP prevalence before the onset of SMC and 1 month after the third treatment in P. falciparum PCR-positive samples from 120 randomly selected children from each treatment arm and an additional 120 randomly selected children from a control group that did not receive SMC. The prevalence of relevant mutations was increased after SMC with AQ/SP. Significant selection was seen for pfcrt 76T (68.5% to 83.0%, P = 0.04), pfdhfr 59R (54.8% to 83.3%, P = 0.0002), and pfdhfr 108N (55.0% to 87.2%, P = 0.0001), with trends toward selection of pfmdr1 86Y, pfdhfr 51I, and pfdhps 437G. After SMC with DP, only borderline selection of wild-type pfmdr1 D1246 (mutant; 7.7% to 0%, P = 0.05) was seen. In contrast to AQ/SP, SMC with DP did not clearly select for known resistance-mediating polymorphisms. SMC with AQ/SP, but not DP, may hasten the development of resistance to components of this regimen. (This study has been registered at ClinicalTrials.gov under registration no. NCT00941785.).

Published
2014

21. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Author

Sagara, Issaka, Beavogui, Abdoul Habib, Zongo, Issaka, Soulama, Issiaka, Borghini-Fuhrer, Isabelle, Fofana, Bakary, Traore, Aliou, Diallo, Nouhoum, Diakite, Hamadoun, Togo, Amadou H, Koumare, Sekou, Keita, Mohamed, Camara, Daouda, Somé, Anyirékun F, Coulibaly, Aboubacar S, Traore, Oumar B, Dama, Souleymane, Goita, Siaka, Djimde, Moussa, Bamadio, Amadou, Dara, Niawanlou, Maiga, Hamma, Sidibe, Bouran, Dao, Francois, Coulibaly, Moctar, Alhousseini, Mohamed Lamine, Niangaly, Hamidou, Sangare, Boubou, Diarra, Modibo, Coumare, Samba, Kabore, Moïse J T, Ouattara, San Maurice, Barry, Aissata, Kargougou, Désiré, Diarra, Amidou, Henry, Noelie, Soré, Harouna, Bougouma, Edith C, Thera, Ismaila, Compaore, Yves D, Sutherland, Colin J, Sylla, Malick Minkael, Nikiema, Frederic, Diallo, Mamadou Saliou, Dicko, Alassane, Picot, Stephane, Borrmann, Steffen, Duparc, Stephan, Miller, Robert M, Doumbo, Ogobara K, Shin, Jangsik, Gil, Jose Pedro, Björkman, Anders, Ouedraogo, Jean-Bosco, Sirima, Sodiomon B, and Djimde, Abdoulaye A

Published
2018
Full Text
View/download PDF

22. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial

Author

Dicko, Alassane, primary, Ouedraogo, Jean-Bosco, additional, Zongo, Issaka, additional, Sagara, Issaka, additional, Cairns, Matthew, additional, Yerbanga, Rakiswendé Serge, additional, Issiaka, Djibrilla, additional, Zoungrana, Charles, additional, Sidibe, Youssoufa, additional, Tapily, Amadou, additional, Nikièma, Frédéric, additional, Sompougdou, Frédéric, additional, Sanogo, Koualy, additional, Kaya, Mahamadou, additional, Yalcouye, Hama, additional, Dicko, Oumar Mohamed, additional, Diarra, Modibo, additional, Diarra, Kalifa, additional, Thera, Ismaila, additional, Haro, Alassane, additional, Sienou, Abdoul Aziz, additional, Traore, Seydou, additional, Mahamar, Almahamoudou, additional, Dolo, Amagana, additional, Kuepfer, Irene, additional, Snell, Paul, additional, Grant, Jane, additional, Webster, Jayne, additional, Milligan, Paul, additional, Lee, Cynthia, additional, Ockenhouse, Christian, additional, Ofori-Anyinam, Opokua, additional, Tinto, Halidou, additional, Djimde, Abdoulaye, additional, Chandramohan, Daniel, additional, and Greenwood, Brian, additional

Published
2023
Full Text
View/download PDF

23. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case-control studies in 5 countries

Author

Cairns, Matthew, Ceesay, Serign Jawo, Sagara, Issaka, Zongo, Issaka, Kessely, Hamit, Gamougam, Kadidja, Diallo, Abdoulaye, Ogboi, Johnbull Sonny, Moroso, Diego, Van Hulle, Suzanne, Eloike, Tony, Snell, Paul, Scott, Susana, Merle, Corinne, Bojang, Kalifa, Ouedraogo, Jean Bosco, Dicko, Alassane, Ndiaye, Jean-Louis, and Milligan, Paul

Subjects
Seasonal variations (Diseases), Malaria -- Prevention -- Drug therapy -- Statistics, Public health, Biological sciences
Abstract

Background Seasonal malaria chemoprevention (SMC) has shown high protective efficacy against clinical malaria and severe malaria in a series of clinical trials. We evaluated the effectiveness of SMC treatments against clinical malaria when delivered at scale through national malaria control programmes in 2015 and 2016. Methods and findings Case-control studies were carried out in Mali and The Gambia in 2015, and in Burkina Faso, Chad, Mali, Nigeria, and The Gambia in 2016. Children aged 3-59 months presenting at selected health facilities with microscopically confirmed clinical malaria were recruited as cases. Two controls per case were recruited concurrently (on or shortly after the day the case was detected) from the neighbourhood in which the case lived. The primary exposure was the time since the most recent course of SMC treatment, determined from SMC recipient cards, caregiver recall, and administrative records. Conditional logistic regression was used to estimate the odds ratio (OR) associated with receipt of SMC within the previous 28 days, and SMC 29 to 42 days ago, compared with no SMC in the past 42 days. These ORs, which are equivalent to incidence rate ratios, were used to calculate the percentage reduction in clinical malaria incidence in the corresponding time periods. Results from individual countries were pooled in a random-effects meta-analysis. In total, 2,126 cases and 4,252 controls were included in the analysis. Across the 7 studies, the mean age ranged from 1.7 to 2.4 years and from 2.1 to 2.8 years among controls and cases, respectively; 42.2%-50.9% and 38.9%-46.9% of controls and cases, respectively, were male. In all 7 individual case-control studies, a high degree of personal protection from SMC against clinical malaria was observed, ranging from 73% in Mali in 2016 to 98% in Mali in 2015. The overall OR for SMC within 28 days was 0.12 (95% CI: 0.06, 0.21; p < 0.001), indicating a protective effectiveness of 88% (95% CI: 79%, 94%). Effectiveness against clinical malaria for SMC 29-42 days ago was 61% (95% CI: 47%, 72%). Similar results were obtained when the analysis was restricted to cases with parasite density in excess of 5,000 parasites per microlitre: Protective effectiveness 90% (95% CI: 79%, 96%; P Conclusions SMC administered as part of routine national malaria control activities provided a very high level of personal protection against clinical malaria over 28 days post-treatment, similar to the efficacy observed in clinical trials. The case-control design used in this study can be used at intervals to ensure SMC treatments remain effective., Author(s): Matthew Cairns 1,*, Serign Jawo Ceesay 2, Issaka Sagara 3, Issaka Zongo 4, Hamit Kessely 5, Kadidja Gamougam 5, Abdoulaye Diallo 6, Johnbull Sonny Ogboi 7, Diego Moroso 8, [...]

Published
2021
Full Text
View/download PDF

24. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial

Author

Sagara, Issaka, Beavogui, Abdoul Habib, Zongo, Issaka, Soulama, Issiaka, Borghini-Fuhrer, Isabelle, Fofana, Bakary, Camara, Daouda, Somé, Anyirékun F, Coulibaly, Aboubacar S, Traore, Oumar B, Dara, Niawanlou, Kabore, Moïse J T, Thera, Ismaila, Compaore, Yves D, Sylla, Malick Minkael, Nikiema, Frederic, Diallo, Mamadou Saliou, Dicko, Alassane, Gil, Jose Pedro, Borrmann, Steffen, Duparc, Stephan, Miller, Robert M, Doumbo, Ogobara K, Shin, Jangsik, Bjorkman, Anders, Ouedraogo, Jean-Bosco, Sirima, Sodiomon B, and Djimdé, Abdoulaye A

Published
2016
Full Text
View/download PDF

25. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Author

Datoo, Mehreen S, Dicko, Alassane, Tinto, Halidou, Ouédraogo, Jean-Bosco, Hamaluba, Mainga, Olotu, Ally, Beaumont, Emma, Ramos Lopez, Fernando, Natama, Hamtandi Magloire, Weston, Sophie, Chemba, Mwajuma, Compaore, Yves Daniel, Issiaka, Djibrilla, Salou, Diallo, Some, Athanase M, Omenda, Sharon, Lawrie, Alison, Bejon, Philip, Rao, Harish, Chandramohan, Daniel, Roberts, Rachel, Bharati, Sandesh, Stockdale, Lisa, Gairola, Sunil, Greenwood, Brian M, Ewer, Katie J, Bradley, John, Kulkarni, Prasad S, Shaligram, Umesh, Hill, Adrian V S, Mahamar, Almahamoudou, Sanogo, Koualy, Sidibe, Youssoufa, Diarra, Kalifa, Samassekou, Mamoudou, Attaher, Oumar, Tapily, Amadou, Diallo, Makonon, Dicko, Oumar Mohamed, Kaya, Mahamadou, Maguiraga, Seydina Oumar, Sankare, Yaya, Yalcouye, Hama, Diarra, Soumaila, Niambele, Sidi Mohamed, Thera, Ismaila, Sagara, Issaka, Sylla, Mala, Dolo, Amagana, Misidai, Nsajigwa, Simando, Sylvester, Msami, Hania, Juma, Omary, Gutapaka, Nicolaus, Paul, Rose, Mswata, Sarah, Sasamalo, Ibrahim, Johaness, Kasmir, Sultan, Mwantumu, Alexander, Annastazia, Kimaro, Isaac, Lwanga, Kauye, Mtungwe, Mwajuma, Khamis, Kassim, Rugarabam, Lighton, Kalinga, Wilmina, Mohammed, Mohammed, Kamange, Janeth, Msangi, Jubilate, Mwaijande, Batuli, Mtaka, Ivanny, Mhapa, Matilda, Mlaganile, Tarsis, Mbaga, Thabit, Yerbanga, Rakiswende Serge, Samtouma, Wendkouni, Sienou, Abdoul Aziz, Kabre, Zachari, Ouedraogo, Wendinpui Jedida Muriel, Yarbanga, G Armel Bienvenu, Zongo, Issaka, Savadogo, Hamade, Sanon, Joseph, Compaore, Judicael, Kere, Idrissa, Yoni, Ferdinand Lionel, Sanre, Tewende Martine, Ouattara, Seydou Bienvenu, Provstgaard-Morys, Samuel, Woods, Danielle, Snow, Robert W., Amek, Nyaguara, Ngetsa, Caroline J., Ochola-Oyier, Lynette Isabella, Musyoki, Jennifer, Munene, Marianne, Mumba, Noni, Adetifa, Uche Jane, Muiruri, Charles Mwangi, Mwawaka, Jimmy Shangala, Mwaganyuma, Mwatasa Hussein, Ndichu, Martha Njeri, Weya, Joseph Ochieng, Njogu, Kelvin, Grant, Jane, Webster, Jayne, Lakhkar, Anand, Ido, N. Félix André, Traore, Ousmane, Tahita, Marc Christian, Bonko, Massa dit Achille, Rouamba, Toussaint, Ouedraogo, D. Florence, Soma, Rachidatou, Millogo, Aida, Ouedraogo, Edouard, Sorgho, Faizatou, Konate, Fabé, and Valea, Innocent

Abstract

Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites.

Published
2024
Full Text
View/download PDF

26. Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data

Author

Mansoor, Rashid, Commons, Robert J, Douglas, Nicholas M, Abuaku, Benjamin, Achan, Jane, Adam, Ishag, Adjei, George O, Adjuik, Martin, Alemayehu, Bereket H, Allan, Richard, Allen, Elizabeth N, Anvikar, Anupkumar R, Arinaitwe, Emmanuel, Ashley, Elizabeth A, Ashurst, Hazel, Asih, Puji BS, Bakyaita, Nathan, Barennes, Hubert, Barnes, Karen I, Basco, Leonardo, Bassat, Quique, Baudin, Elisabeth, Bell, David J, Bethell, Delia, Bjorkman, Anders, Boulton, Caroline, Bousema, Teun, Brasseur, Philippe, Bukirwa, Hasifa, Burrow, Rebekah, Carrara, Verena I, Cot, Michel, D'Alessandro, Umberto, Das, Debashish, Das, Sabyasachi, Davis, Timothy ME, Desai, Meghna, Djimde, Abdoulaye A, Dondorp, Arjen M, Dorsey, Grant, Drakeley, Chris J, Duparc, Stephan, Espie, Emmanuelle, Etard, Jean-Francois, Falade, Catherine, Faucher, Jean Francois, Filler, Scott, Fogg, Carole, Fukuda, Mark, Gaye, Oumar, Genton, Blaise, Rahim, Awab Ghulam, Gilayeneh, Julius, Gonzalez, Raquel, Grais, Rebecca F, Grandesso, Francesco, Greenwood, Brian, Grivoyannis, Anastasia, Hatz, Christoph, Hodel, Eva Maria, Humphreys, Georgina S, Hwang, Jimee, Ishengoma, Deus, Juma, Elizabeth, Kachur, S Patrick, Kager, Piet A, Kamugisha, Erasmus, Kamya, Moses R, Karema, Corine, Kayentao, Kassoum, Kazienga, Adama, Kiechel, Jean-Rene, Kofoed, Poul-Erik, Koram, Kwadwo, Kremsner, Peter G, Lalloo, David G, Laman, Moses, Lee, Sue J, Lell, Bertrand, Maiga, Amelia W, Martensson, Andreas, Mayxay, Mayfong, Mbacham, Wilfred, McGready, Rose, Menan, Herve, Menard, Didier, Mockenhaupt, Frank, Moore, Brioni R, Muller, Olaf, Nahum, Alain, Ndiaye, Jean-Louis, Newton, Paul N, Ngasala, Billy E, Nikiema, Frederic, Nji, Akindeh M, Noedl, Harald, Nosten, Francois, Ogutu, Bernhards R, Ojurongbe, Olusola, Osorio, Lyda, Ouedraogo, Jean-Bosco, Owusu-Agyei, Seth, Pareek, Anil, Penali, Louis K, Piola, Patrice, Plucinski, Mateusz, Premji, Zul, Ramharter, Michael, Richmond, Caitlin L, Rombo, Lars, Rosenthal, Philip J, Salman, Sam, Same-Ekobo, Albert, Sibley, Carol, Sirima, Sodiomon B, Smithuis, Frank M, Some, Fabrice A, Staedke, Sarah G, Starzengruber, Peter, Strub-Wourgaft, Nathalie, Sutanto, Inge, Swarthout, Todd D, Syafruddin, Din, Talisuna, Ambrose O, Taylor, Walter R, Temu, Emmanuel A, Thwing, Julie I, Tinto, Halidou, Tjitra, Emiliana, Toure, Offianan A, Tran, T Hien, Ursing, Johan, Valea, Innocent, Valentini, Giovanni, van Vugt, Michele, von Seidlein, Lorenz, Ward, Stephen A, Were, Vincent, White, Nicholas J, Woodrow, Charles J, Yavo, William, Yeka, Adoke, Zongo, Issaka, Simpson, Julie A, Guerin, Philippe J, Stepniewska, Kasia, Price, Ric N, Roper, Cally, Resistance, WorldWide Antimalarial, WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Epidémiologie des Maladies Chroniques en zone tropicale (EpiMaCT), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-OmégaHealth (ΩHealth), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Group, WorldWide Antimalarial Resistance Network Falciparum Haematology Study, Mansoor, R, Ashley, EA, Ashurst, H, Burrow, R, Carrara, VI, Das, D, Dondorp, AM, Humphreys, GS, Lee, SJ, Mayxay, M, McGready, R, Newton, PN, Nosten, F, Richmond, CL, Sibley, C, Smithuis, FM, Taylor, WR, Tran, TH, von Seidlein, L, White, NJ, Woodrow, CJ, Guerin, PJ, Stepniewska, K, Price, RN, AII - Infectious diseases, Intensive Care Medicine, Infectious diseases, APH - Global Health, and APH - Quality of Care

Subjects
Infectious Medicine, Plasmodium falciparum, wh_120, Infektionsmedicin, Severe anaemia, Parasitemia, wa_530, Antimalarials, Non-artemisinin-based therapy, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, parasitic diseases, qv_256, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Malaria, Falciparum, Child, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Pooled analysis of individual patient data, Anemia, Public Health, Global Health, Social Medicine and Epidemiology, General Medicine, Artemisinin-based therapy, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Malaria, wc_750, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Haemoglobin
Abstract

Background Plasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia. Methods Individual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin < 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall ≥ 25% at day 3 and day 7. Results A total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0–19.7 g/dL) in Africa, 11.6 g/dL (range 5.0–20.0 g/dL) in Asia and 12.3 g/dL (range 6.9–17.9 g/dL) in South America. Moderately severe anaemia (Hb < 7g/dl) was present in 8.4% (4284/50,859) of patients from Africa, 3.3% (606/18,451) from Asia and 0.1% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age < 1 compared to ≥ 12 years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39–3.05], p < 0.001). Conclusions In patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.

Published
2022
Full Text
View/download PDF

28. Whole-Genome Scans Provide Evidence of Adaptive Evolution in Malawian Plasmodium falciparum Isolates

Author

Ocholla, Harold, Preston, Mark D., Mipando, Mwapatsa, Jensen, Anja T. R., Campino, Susana, MacInnis, Bronwyn, Alcock, Daniel, Terlouw, Anja, Zongo, Issaka, Oudraogo, Jean-Bosco, Djimde, Abdoulaye A., Assefa, Samuel, Doumbo, Ogobara K., Borrmann, Steffen, Nzila, Alexis, Marsh, Kevin, Fairhurst, Rick M., Nosten, Francois, Anderson, Tim J. C, Kwiatkowski, Dominic P., Craig, Alister, Clark, Taane G., and Montgomery, Jacqui

Published
2014

29. Plasmo View: A Web-based Resource to Visualise Global Plasmodium falciparum Genomic Variation

Author

Preston, Mark D., Assefa, Samuel A., Ocholla, Harold, Sutherland, Colin J., Borrmann, Steffen, Nzila, Alexis, Michon, Pascal, Hien, Tran Tinh, Bousema, Teun, Drakeley, Christopher J., Zongo, Issaka, Ouédraogo, Jean-Bosco, Djimde, Abdoulaye A., Doumbo, Ogobara K., Nosten, Francois, Fairhurst, Rick M., Conway, David J., Roper, Cally, and Clark, Taane G.

Published
2014

31. Factors Influencing Second and Third Dose Observance during Seasonal Malaria Chemoprevention (SMC): A Quantitative Study in Burkina Faso, Mali, and Niger

Author

Somé, Anyirékun Fabrice, primary, Zongo, Issaka, additional, Sagara, Issaka, additional, Ibrahim, Alkassoum, additional, Ahanhanzo, Césaire Damien, additional, Agbanouvi-agassi, Edoh Eddie, additional, Sayi, Dona Alain, additional, Paré, Lea, additional, Kabré, Zachari, additional, Nikiéma, Frédéric, additional, Bazié, Thomas, additional, Ouédraogo, Sylvin, additional, Sombié, Issaka, additional, Dicko, Alassane, additional, Adehossi, Eric, additional, Ouedraogo, Jean Bosco, additional, and Dabiré, K. Roch, additional

Published
2022
Full Text
View/download PDF

32. Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy : an individual participant data meta-analysis

Author

Dahal, Prabin, Simpson, Julie Anne, Abdulla, Salim, Achan, Jane, Adam, Ishag, Agarwal, Aarti, Allan, Richard, Anvikar, Anupkumar R., Ashley, Elizabeth A., Bassat, Quique, Borrmann, Steffen, Bousema, Teun, Bukirwa, Hasifa, Carrara, Verena, I, Corsi, Marco, D'Alessandro, Umberto, Davis, Timothy M. E., Deloron, Philippe, Desai, Meghna, Dimbu, Pedro Rafael, Djalle, Djibrine, Djimde, Abdoulaye, Dorsey, Grant, Drakeley, Chris J., Duparc, Stephan, Edstein, Michael D., Espie, Emmanuelle, Faiz, Abul, Falade, Catherine, Fanello, Caterina, Faucher, Jean-Francois, Faye, Babacar, Fortes, Filomeno de Jesus, Gadalla, Nahla B., Gaye, Oumar, Gil, J. Pedro, Gilayeneh, Julius, Greenwood, Brian, Grivoyannis, Anastasia, Hien, Tran Tinh, Hwang, Jimee, Janssens, Bart, Juma, Elizabeth, Kamugisha, Erasmus, Karema, Corine, Karunajeewa, Harin A., Kiechel, Jean R., Kironde, Fred, Kofoed, Poul-Erik, Kremsner, Peter G., Lee, Sue J., Marsh, Kevin, Mårtensson, Andreas, Mayxay, Mayfong, Menan, Herve, Mens, Petra, Mutabingwa, Theonest K., Ndiaye, Jean-Louis, Ngasala, Billy, Noedl, Harald, Nosten, Francois, Offianan, Andre Toure, Ogutu, Bernhards R., Olliaro, Piero L., Ouedraogo, Jean Bosco, Piola, Patrice, Plowe, Christopher, V, Plucinski, Mateusz M., Pratt, Oliver James, Premji, Zulfikarali, Ramharter, Michael, Rogier, Christophe, Vitare, Primum, Rombo, Lars, Rosenthal, Philip J., Sibley, Carol, Sirima, Sodiomon, Smithuis, Frank, Staedke, Sarah G., Sutanto, Inge, Talisuna, Ambrose Otau, Tarning, Joel, Taylor, Walter R. J., Temu, Emmanuel, Thriemer, Kamala, Thuy-Nhien, Nguyen, Udhayakumar, Venkatachalam, Ursing, Johan D., van Herp, Michel, van Lenthe, Marit, van Vugt, Michele, William, Yavo, Winnips, Cornelis, Zaloumis, Sophie, Zongo, Issaka, White, Nick J., Guerin, Philippe J., Stepniewska, Kasia, Price, Ric N., Arinaitwe, Emmanuel, Dahal, Prabin, Simpson, Julie Anne, Abdulla, Salim, Achan, Jane, Adam, Ishag, Agarwal, Aarti, Allan, Richard, Anvikar, Anupkumar R., Ashley, Elizabeth A., Bassat, Quique, Borrmann, Steffen, Bousema, Teun, Bukirwa, Hasifa, Carrara, Verena, I, Corsi, Marco, D'Alessandro, Umberto, Davis, Timothy M. E., Deloron, Philippe, Desai, Meghna, Dimbu, Pedro Rafael, Djalle, Djibrine, Djimde, Abdoulaye, Dorsey, Grant, Drakeley, Chris J., Duparc, Stephan, Edstein, Michael D., Espie, Emmanuelle, Faiz, Abul, Falade, Catherine, Fanello, Caterina, Faucher, Jean-Francois, Faye, Babacar, Fortes, Filomeno de Jesus, Gadalla, Nahla B., Gaye, Oumar, Gil, J. Pedro, Gilayeneh, Julius, Greenwood, Brian, Grivoyannis, Anastasia, Hien, Tran Tinh, Hwang, Jimee, Janssens, Bart, Juma, Elizabeth, Kamugisha, Erasmus, Karema, Corine, Karunajeewa, Harin A., Kiechel, Jean R., Kironde, Fred, Kofoed, Poul-Erik, Kremsner, Peter G., Lee, Sue J., Marsh, Kevin, Mårtensson, Andreas, Mayxay, Mayfong, Menan, Herve, Mens, Petra, Mutabingwa, Theonest K., Ndiaye, Jean-Louis, Ngasala, Billy, Noedl, Harald, Nosten, Francois, Offianan, Andre Toure, Ogutu, Bernhards R., Olliaro, Piero L., Ouedraogo, Jean Bosco, Piola, Patrice, Plowe, Christopher, V, Plucinski, Mateusz M., Pratt, Oliver James, Premji, Zulfikarali, Ramharter, Michael, Rogier, Christophe, Vitare, Primum, Rombo, Lars, Rosenthal, Philip J., Sibley, Carol, Sirima, Sodiomon, Smithuis, Frank, Staedke, Sarah G., Sutanto, Inge, Talisuna, Ambrose Otau, Tarning, Joel, Taylor, Walter R. J., Temu, Emmanuel, Thriemer, Kamala, Thuy-Nhien, Nguyen, Udhayakumar, Venkatachalam, Ursing, Johan D., van Herp, Michel, van Lenthe, Marit, van Vugt, Michele, William, Yavo, Winnips, Cornelis, Zaloumis, Sophie, Zongo, Issaka, White, Nick J., Guerin, Philippe J., Stepniewska, Kasia, Price, Ric N., and Arinaitwe, Emmanuel

Abstract

Background: The duration of trial follow-up affects the ability to detect recrudescent infections following anti-malarial treatment. The aim of this study was to explore the proportions of recrudescent parasitaemia as ascribed by genotyping captured at various follow-up time-points in treatment efficacy trials for uncomplicated Plasmodium falciparum malaria. Methods: Individual patient data from 83 anti-malarial efficacy studies collated in the WorldWide Antimalarial Resistance Network (WWARN) repository with at least 28 days follow-up were available. The temporal and cumulative distributions of recrudescence were characterized using a Cox regression model with shared frailty on study-sites. Fractional polynomials were used to capture non-linear instantaneous hazard. The area under the density curve (AUC) of the constructed distribution was used to estimate the optimal follow-up period for capturing a P. falciparum malaria recrudescence. Simulation studies were conducted based on the constructed distributions to quantify the absolute overestimation in efficacy due to sub-optimal follow-up. Results: Overall, 3703 recurrent infections were detected in 60 studies conducted in Africa (15,512 children aged < 5 years) and 23 studies conducted in Asia and South America (5272 patients of all ages). Using molecular genotyping, 519 (14.0%) recurrences were ascribed as recrudescent infections. A 28 day artemether-lumefantrine (AL) efficacy trial would not have detected 58% [95% confidence interval (CI) 47-74%] of recrudescences in African children and 32% [95% CI 15-45%] in patients of all ages in Asia/South America. The corresponding estimate following a 42 day dihydroartemisinin-piperaquine (DP) efficacy trial in Africa was 47% [95% CI 19-90%] in children under 5 years old treated with > 48 mg/kg total piperaquine (PIP) dose and 9% [95% CI 0-22%] in those treated with <= 48 mg/kg PIP dose. In absolute terms, the simulation study found that trials limited to 28 days

Published
2022
Full Text
View/download PDF

33. Knowledge, Attitude, and Practice of Health Care Workers in the Management of Peptic Ulcer at the Paul VI and the Bogodogo District Hospitals, in Burkina Faso

Author

None, Somé, Eric Nagaonlé, Zongo, Issaka, Guinganné, Alice Nanelin, Congo, Estelle, Drabo, Maxime Koiné, Sombié, Roger, None, Somé, Eric Nagaonlé, Zongo, Issaka, Guinganné, Alice Nanelin, Congo, Estelle, Drabo, Maxime Koiné, and Sombié, Roger

Abstract

Background: In 2015, peptic ulcer disease (PUD) was cause of 52.3% and 17% of digestive bleeding and death in respectively among in-hospital patients at the gastro-enterology units of the main hospital in Ouagadougou. We aimed to assess the knowledge, attitudes and practices of the health care workers in the management of PUD.Subjects dan Method: It was a descriptive cross-sectional study with a prospective data collection implemented at the Paul VI and the Bogodogo District Hospitals in Ouagadougou (Burkina Faso) from December 15, 2015 to January 25, 2016. A questionnaire was administered to 134 health care workers including medical doctors, nurses and midwives.Results: The mean age was 33 years (Mean= 33.6; SD= 5.84). Females represented 61.9%. Know­ledge levels were good to excellent for general knowledge, symptoms and treatment of PUD. Depending on the agent's qualification, knowledge levels were excellent in all areas for two-thirds to three-quarters of the general practitioners, except for knowledge of additional investigation analyses, where only 47.8% had an excellent knowledge. Depending on the level of education, the level of knowledge was at least good for more than 50% of the agents except for the knowledge of additional investigation analyses where only 45.2 % of the agents of secondary school level had a good knowledge. The main attitudes consisted in managing the patients in emergency and out of an emergency context in 45.8% and 42.2% of the cases, respectively. Regarding the practices, 51.5% of the HCWs systematically requested investigation analyses before starting an aetiological therapy.Conclusion: The PUD knowledge ranks from good to excellent. However, the frequent pre­scription of symptomatic treatments could be the cause of many complications. The promotion of continuous medical education is a good mitigation plan to resolve the issues of knowledge and competence regarding the PUD.Keywords: attitude, knowledge, peptic ulcer disease, practiceCo

Published
2022

34. Additional file 1 of The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone

Author

Cairns, Matthew, Barry, Amadou, Zongo, Issaka, Sagara, Issaka, Yerbanga, Serge R., Diarra, Modibo, Zoungrana, Charles, Issiaka, Djibrilla, Sienou, Abdoul Aziz, Tapily, Amadou, Sanogo, Koualy, Kaya, Mahamadou, Traore, Seydou, Diarra, Kalifa, Yalcouye, Hama, Sidibe, Youssoufa, Haro, Alassane, Thera, Ismaila, Snell, Paul, Grant, Jane, Tinto, Halidou, Milligan, Paul, Chandramohan, Daniel, Greenwood, Brian, Dicko, Alassane, and Ouedraogo, Jean Bosco

Abstract

Additional file 1: Table S1. Number of clinical malaria episodes by time since vaccination in each year of the study, using 90-day periods (as used in the Piecewise Cox regression models). Table S2. Number of clinical malaria episodes by time since vaccination in each year of the study, using 60-day periods (not used in the Piecewise Cox regression models, but provided to show the declining incidence of malaria further into the dry season). Table S3. Number and percentage of children who were scheduled to receive SMC, received SMC, and received all daily SMC doses (full SMC) over the course of the study. Figure S1. Observed hazard function and Cumulative hazard function, and the fitted cumulative hazard and estimated protective efficacy from flexible parametric survival models used to estimate vaccine efficacy in each year of the study. Figure S2. Protective Efficacy of SMC in the first 21 days and first 30 days after SMC received, by cycle. Figure S3. Protective Efficacy by time since the final SMC cycle in each year. Figure S4. Comparison of the SMC protective efficacy profile obtained in this study with the profile estimated for an earlier placebo-controlled trial of SMC.

Published
2022
Full Text
View/download PDF

35. Additional file 1 of Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study

Author

Ward, Charlotte, Phillips, Abimbola, Oresanya, Olusola, Olisenekwu, Gloria, Arogunade, Ekundayo, Mouk��net, Azoukaln��, Beakgoub��, Honor��, De Paul Allambademel, Vincent, Compaor��, Cheick Sa��d, Traor��, Adama, Ouedraogo, Jean-Bosco, Compaor��, Yves Daniel, Zongo, Issaka, Donovan, Laura, Decola, Monica Anna, Smith, Helen, and Baker, Kevin

Abstract

Additional file 1: Table S1. Number and proportion of community distributors observed receiving equipment, by country and local government area (Nigeria) or health district (Burkina Faso and Chad).

Published
2022
Full Text
View/download PDF

36. Additional file 1 of Impact of seasonal RTS,S/AS01E vaccination plus seasonal malaria chemoprevention on the nutritional status of children in Burkina Faso and Mali

Author

Grant, Jane, Sagara, Issaka, Zongo, Issaka, Cairns, Matthew, Yerbanga, Rakiswend�� Serge, Diarra, Modibo, Zoungrana, Charles, Issiaka, Djibrilla, Niki��ma, Fr��d��ric, Sompougdou, Fr��d��ric, Tapily, Amadou, Kaya, Mahamadou, Haro, Alassane, Sanogo, Koualy, Sienou, Abdoul Aziz, Traore, Seydou, Thera, Ismaila, Yalcouye, Hama, Kuepfer, Irene, Snell, Paul, Milligan, Paul, Ockenhouse, Christian, Ofori-Anyinam, Opokua, Tinto, Halidou, Djimde, Abdoulaye, Chandramohan, Daniel, Greenwood, Brian, Dicko, Alassane, and Ou��draogo, Jean-Bosco

Subjects
parasitic diseases, population characteristics, geographic locations
Abstract

Additional file 1: Figure S1. Prevalence of severe nutritional outcomes in study children Burkina Faso and Mali over the study period 2017-2019 (mITT population). Table S1. Difference in mean Z-scores for nutritional indicators between study arms in Burkina Faso and Mali at the end of the malaria transmission season surveys (mITT population). Figure S2. Cumulative distribution functions of weight-for-height and MUAC-for-age in study children between study arms over the study period 2017-2019, centred on the Z-score cut-off for moderate malnutrition (mITT population). Figure S3. Cumulative distribution functions of weight-for-age and height-for-age in study children between study arms over the study period 2017-2019, centred on the Z-score cut-off for moderate malnutrition (mITT population). Table S2. Difference in mean changes in anthropometric measurements between study arms in Burkina Faso and Mali at the end of transmission season surveys between 2017-2018, 2018-2019 and 2017-2019. Table S3. Test of interaction between country and treatment arm. Figure S4. Prevalence of key nutritional outcomes in study children between study arms (SMC, RTS,S/AS01E and combined SMC + RTS,S/AS01E) in Burkina Faso (a) and Mali (b) over the study period 2017-2019 (mITT population). Table S4. Prevalence and prevalence ratios of primary outcomes between study arms in Burkina Faso and Mali at the end of the malaria transmission season surveys (per protocol population).

Published
2022
Full Text
View/download PDF

37. Additional file 2 of Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study

Author

Ward, Charlotte, Phillips, Abimbola, Oresanya, Olusola, Olisenekwu, Gloria, Arogunade, Ekundayo, Mouk��net, Azoukaln��, Beakgoub��, Honor��, De Paul Allambademel, Vincent, Compaor��, Cheick Sa��d, Traor��, Adama, Ouedraogo, Jean-Bosco, Compaor��, Yves Daniel, Zongo, Issaka, Donovan, Laura, Decola, Monica Anna, Smith, Helen, and Baker, Kevin

Abstract

Additional file 2. Additional quotes.

Published
2022
Full Text
View/download PDF

38. The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine

Author

Sagara, Issaka, primary, Zongo, Issaka, additional, Cairns, Matthew, additional, Yerbanga, Rakiswendé Serge, additional, Mahamar, Almahamoudou, additional, Nikièma, Frédéric, additional, Tapily, Amadou, additional, Sompougdou, Frédéric, additional, Diarra, Modibo, additional, Zoungrana, Charles, additional, Issiaka, Djibrilla, additional, Haro, Alassane, additional, Sanogo, Koualy, additional, Aziz Sienou, Abdoul, additional, Kaya, Mahamadou, additional, Traore, Seydou, additional, Thera, Ismaila, additional, Diarra, Kalifa, additional, Dolo, Amagana, additional, Kuepfer, Irene, additional, Snell, Paul, additional, Milligan, Paul, additional, Ockenhouse, Christian, additional, Ofori-Anyinam, Opokua, additional, Tinto, Halidou, additional, Djimde, Abdoulaye, additional, Ouedraogo, Jean Bosco, additional, Dicko, Alassane, additional, Chandramohan, Daniel, additional, and Greenwood, Brian, additional

Published
2021
Full Text
View/download PDF

39. Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus

Author

Hema-Ouangraoua, Soumeya, primary, Tranchot-Diallo, Juliette, additional, Zongo, Issaka, additional, Kabore, Nongodo Firmin, additional, Nikièma, Frédéric, additional, Yerbanga, Rakiswende Serge, additional, Tinto, Halidou, additional, Chandramohan, Daniel, additional, Ouedraogo, Georges-Anicet, additional, Greenwood, Brian, additional, and Ouedraogo, Jean-Bosco, additional

Published
2021
Full Text
View/download PDF

40. The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone.

Author

Cairns, Matthew, Barry, Amadou, Zongo, Issaka, Sagara, Issaka, Yerbanga, Serge R., Diarra, Modibo, Zoungrana, Charles, Issiaka, Djibrilla, Sienou, Abdoul Aziz, Tapily, Amadou, Sanogo, Koualy, Kaya, Mahamadou, Traore, Seydou, Diarra, Kalifa, Yalcouye, Hama, Sidibe, Youssoufa, Haro, Alassane, Thera, Ismaila, Snell, Paul, and Grant, Jane

Subjects
MALARIA vaccines, MALARIA, CHEMOPREVENTION, BOOSTER vaccines, SEASONS, MALARIA prevention, PROTOZOA, VACCINES, IMMUNOGLOBULINS, IMMUNIZATION, CLINICAL trials, RESEARCH funding
Abstract

Background: A recent trial of 5920 children in Burkina Faso and Mali showed that the combination of seasonal vaccination with the RTS,S/AS01E malaria vaccine (primary series and two seasonal boosters) and seasonal malaria chemoprevention (four monthly cycles per year) was markedly more effective than either intervention given alone in preventing clinical malaria, severe malaria, and deaths from malaria.Methods: In order to help optimise the timing of these two interventions, trial data were reanalysed to estimate the duration of protection against clinical malaria provided by RTS,S/AS01E when deployed seasonally, by comparing the group who received the combination of SMC and RTS,S/AS01E with the group who received SMC alone. The duration of protection from SMC was also estimated comparing the combined intervention group with the group who received RTS,S/AS01E alone. Three methods were used: Piecewise Cox regression, Flexible parametric survival models and Smoothed Schoenfeld residuals from Cox models, stratifying on the study area and using robust standard errors to control for within-child clustering of multiple episodes.Results: The overall protective efficacy from RTS,S/AS01E over 6 months was at least 60% following the primary series and the two seasonal booster doses and remained at a high level over the full malaria transmission season. Beyond 6 months, protective efficacy appeared to wane more rapidly, but the uncertainty around the estimates increases due to the lower number of cases during this period (coinciding with the onset of the dry season). Protection from SMC exceeded 90% in the first 2-3 weeks post-administration after several cycles, but was not 100%, even immediately post-administration. Efficacy begins to decline from approximately day 21 and then declines more sharply after day 28, indicating the importance of preserving the delivery interval for SMC cycles at a maximum of four weeks.Conclusions: The efficacy of both interventions was highest immediately post-administration. Understanding differences between these interventions in their peak efficacy and how rapidly efficacy declines over time will help to optimise the scheduling of SMC, malaria vaccination and the combination in areas of seasonal transmission with differing epidemiology, and using different vaccine delivery systems.Trial Registration: The RTS,S-SMC trial in which these data were collected was registered at clinicaltrials.gov: NCT03143218. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention

Author

Chandramohan, Daniel, primary, Zongo, Issaka, additional, Sagara, Issaka, additional, Cairns, Matthew, additional, Yerbanga, Rakiswendé-Serge, additional, Diarra, Modibo, additional, Nikièma, Frédéric, additional, Tapily, Amadou, additional, Sompougdou, Frédéric, additional, Issiaka, Djibrilla, additional, Zoungrana, Charles, additional, Sanogo, Koualy, additional, Haro, Alassane, additional, Kaya, Mahamadou, additional, Sienou, Abdoul-Aziz, additional, Traore, Seydou, additional, Mahamar, Almahamoudou, additional, Thera, Ismaila, additional, Diarra, Kalifa, additional, Dolo, Amagana, additional, Kuepfer, Irene, additional, Snell, Paul, additional, Milligan, Paul, additional, Ockenhouse, Christian, additional, Ofori-Anyinam, Opokua, additional, Tinto, Halidou, additional, Djimde, Abdoulaye, additional, Ouédraogo, Jean-Bosco, additional, Dicko, Alassane, additional, and Greenwood, Brian, additional

Published
2021
Full Text
View/download PDF

42. Delivery of Seasonal Malaria Chemoprevention With Enhanced Infection Prevention and Control Measures During the COVID-19 Pandemic in Nigeria, Burkina Faso and Chad: A Cross-sectional Study

Author

Ward, Charlotte, primary, Phillips, Abimbola, additional, Oresanya, Olusola, additional, Olisenekwu, Gloria, additional, Arogunade, Ekundayo, additional, Moukénet, Azoukalné, additional, Beakgoubé, Honoré, additional, Allambademel, Vincent de Paul, additional, Compaoré, Cheick Saïd, additional, Traoré, Adama, additional, Ouedraogo, Jean-Bosco, additional, Compaoré, Yves Daniel, additional, Zongo, Issaka, additional, Donovan, Laura, additional, Decola, Monica Anna, additional, Smith, Helen, additional, and Baker, Kevin, additional

Published
2021
Full Text
View/download PDF

43. Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso

Author

Beshir, Khalid B., primary, Diallo, Nouhoum, additional, Somé, Fabrice A., additional, Sombie, Salif, additional, Zongo, Issaka, additional, Fofana, Bakary, additional, Traore, Aliou, additional, Dama, Souleymane, additional, Bamadio, Amadou, additional, Traore, Oumar B., additional, Coulibaly, Sam A., additional, Maurice, Ouattara S., additional, Diarra, Amidou, additional, Kaboré, Jean Moise, additional, Kodio, Aly, additional, Togo, Amadou Hamidou, additional, Dara, Niawanlou, additional, Coulibaly, Moctar, additional, Dao, Francois, additional, Nikiema, Frederic, additional, Compaore, Yves D., additional, Kabore, Naomie T., additional, Barry, Nouhoun, additional, Soulama, Issiaka, additional, Sagara, Issaka, additional, Sirima, Sodiomon B., additional, Ouédraogo, Jean-Bosco, additional, Djimde, Abdoulaye, additional, and Sutherland, Colin J., additional

Published
2021
Full Text
View/download PDF

45. Additional file 3 of Nutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria

Author

de Wit, Mariken, Cairns, Matthew, Compaoré, Yves Daniel, Sagara, Issaka, Kuepfer, Irene, Zongo, Issaka, Barry, Amadou, Diarra, Modibo, Tapily, Amadou, Coumare, Samba, Thera, Ismaila, Nikiema, Frederic, Yerbanga, R. Serge, Guissou, Rosemonde M., Tinto, Halidou, Dicko, Alassane, Chandramohan, Daniel, Greenwood, Brian, and Ouedraogo, Jean Bosco

Abstract

Additional file 3: Table S1. Association of baseline variables with low MUAC-for-age in two cohorts in Burkina Faso. Table S2. Association of baseline variables with stunting, wasting and underweight in 2016 in Burkina Faso.

Published
2021
Full Text
View/download PDF

46. Additional file 4 of Nutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria

Author

de Wit, Mariken, Cairns, Matthew, Compaoré, Yves Daniel, Sagara, Issaka, Kuepfer, Irene, Zongo, Issaka, Barry, Amadou, Diarra, Modibo, Tapily, Amadou, Coumare, Samba, Thera, Ismaila, Nikiema, Frederic, Yerbanga, R. Serge, Guissou, Rosemonde M., Tinto, Halidou, Dicko, Alassane, Chandramohan, Daniel, Greenwood, Brian, and Ouedraogo, Jean Bosco

Abstract

Additional file 4: Table S1. Association of baseline variables with low MUAC-for-age in two cohorts in Mali. Table S2. Association of baseline variables with stunting, wasting and underweight in 2016 in Mali.

Published
2021
Full Text
View/download PDF

47. Additional file 2 of Nutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria

Author

de Wit, Mariken, Cairns, Matthew, Compaoré, Yves Daniel, Sagara, Issaka, Kuepfer, Irene, Zongo, Issaka, Barry, Amadou, Diarra, Modibo, Tapily, Amadou, Coumare, Samba, Thera, Ismaila, Nikiema, Frederic, Yerbanga, R. Serge, Guissou, Rosemonde M., Tinto, Halidou, Dicko, Alassane, Chandramohan, Daniel, Greenwood, Brian, and Ouedraogo, Jean Bosco

Abstract

Additional file 2: Table S1. Association of baseline variables with low MUAC-for-age in two cohorts.

Published
2021
Full Text
View/download PDF

48. Asymptomatic Malaria Carriage in South-Western Burkina Faso: An Epidemiological Analysis

Author

This research was funded by the French Initiative 5% Expertise France. The Grant Number is 15SANIN213., Zongo, Issaka, Somé, Anthony, Some, Eric Nagaonle, Ouattara, Mamadou, Dahounto, Amal, Pennetier, Cédric, Moiroux, Nicolas, Dabiré, Roch K., This research was funded by the French Initiative 5% Expertise France. The Grant Number is 15SANIN213., Zongo, Issaka, Somé, Anthony, Some, Eric Nagaonle, Ouattara, Mamadou, Dahounto, Amal, Pennetier, Cédric, Moiroux, Nicolas, and Dabiré, Roch K.

Abstract

Background: Burkina Faso is challenged by rise in malaria incidence and insecticide and drug resistance. We investigated the prevalence of asymptomatic infection of Plasmodium falciparum. over three surveys.Subjects dan Method: We conducted repeated cross-sectional surveys in September and December 2016 and June 2017 in Diebougou health district. An initial census identified 4,028 subjects aged 6 months to 18 years. The independent variables included the age or date of birth, dependant were the area of residence, the use of bed nets, presence of not of parasites, the period of the surveys and the presence or absence of clinical signs/symptoms/fever, the gender. We used electronic case report forms for data collection, then uploaded into electronic tablets PCs, transferred to a central server. Data were analyzed with R version 3.4.3 software. Baseline charac­teristics were described using descriptive statistics. A bivariate analysis was done to describe the overall malaria prevalence using Chi-squared or Fisher Exact test. Simple and multiple logistic regressions served to determine effect of socio-demographic characteristics and season on both symptomatic and asymptomatic malaria cases.Results: Three malaria active case detection surveys were conducted on 2,839, 2,594 and 2,337 eligible subjects in September 2016, December 2016, and June 2017 respectively. There was high proportion of parasitemia ranging from 31.6% to 43.5% whereas malaria clinical cases ranged from 6.8% in June to 23.81% in September. Age, gender, season, and village variables were significantly associated with asymptomatic malaria carriage. Sleeping under a bednet the night before the survey was found to be protective against asymptomatic malaria.Conclusion: This study has reported high prevalence of malaria infection. The young population was more concerned and September was the period of highest carriage.Keywords: asymptomatic malaria carriage, active case detection, age.Correspondence: Issaka Z

Published
2021

49. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing

Author

Manske, Magnus, Miotto, Olivo, Campino, Susana, Auburn, Sarah, Almagro-Garcia, Jacob, Maslen, Gareth, O’Brien, Jack, Djimde, Abdoulaye, Doumbo, Ogobara, Zongo, Issaka, Ouedraogo, Jean-Bosco, Michon, Pascal, Mueller, Ivo, Siba, Peter, Nzila, Alexis, Borrmann, Steffen, Kiara, Steven M., Marsh, Kevin, Jiang, Hongying, Su, Xin-Zhuan, Amaratunga, Chanaki, Fairhurst, Rick, Socheat, Duong, Nosten, Francois, Imwong, Mallika, White, Nicholas J., Sanders, Mandy, Anastasi, Elisa, Alcock, Dan, Drury, Eleanor, Oyola, Samuel, Quail, Michael A., Turner, Daniel J., Ruano-Rubio, Valentin, Jyothi, Dushyanth, Amenga-Etego, Lucas, Hubbart, Christina, Jeffreys, Anna, Rowlands, Kate, Sutherland, Colin, Roper, Cally, Mangano, Valentina, Modiano, David, Tan, John C., Ferdig, Michael T., Amambua-Ngwa, Alfred, Conway, David J., Takala-Harrison, Shannon, Plowe, Christopher V., Rayner, Julian C., Rockett, Kirk A., Clark, Taane G., Newbold, Chris I., Berriman, Matthew, MacInnis, Bronwyn, and Kwiatkowski, Dominic P.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results